Skip to main content

Advertisement

SpringerLink
Log in

KDM5A regulates the growth and gefitinib drug resistance against human lung adenocarcinoma cells

  • Original Article
  • Published:
3 Biotech Aims and scope Submit manuscript

Abstract

KDM5A, a histone demethylase, has been shown to be involved in several cancer-related process. The present study was undertaken to explore the role and therapeutic potential of KDM5A in human lung adenocarcinoma. The results of the qRT-PCR, immunohistochemistry, and western blotting showed significant upregulation of KDM5A expression in lung adenocarcinoma tissues and cell lines. The RNA interference-mediated silencing of KDM5A in lung adenocarcinoma cell line SK-LU-1 led to significant inhibition of in vitro cell proliferation via induction of apoptosis. The induction of apoptosis in SK-LU-1 lung adenocarcinoma cells was concomitant with upregulation of Bax and downregulation of Bcl-2 expression. In contrary, overexpression of KDM5A prompted the proliferation of SK-LU-1 lung adenocarcinoma cells. Interestingly, the SK-LU-1 cancer cells showed remarkably higher sensitivity to gefitinib under KDM5A transcriptional knockdown. Taken together, KDM5A is significantly upregulated in human lung adenocarcinoma and regulates the proliferation of the lung adenocarcinoma cells. These findings suggest potential of KDM5A to act as a therapeutic target for the management of human lung adenocarcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Availability of data and materials

Available on request.

References

  • Banelli B, Carra E, Barbieri F, Würth R, Parodi F, Pattarozzi A, Carosio R, Forlani A, Allemanni G, Marubbi D, Florio T (2015) The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma. Cell Cycle 14:3418–3429

    Article  CAS  Google Scholar 

  • Cui J, Quan M, Xie D, Gao Y, Guha S, Fallon MB, Chen J, Xie K (2019) A novel KDM5A/MPC-1 signaling pathway promotes pancreatic cancer progression via redirecting mitochondrial pyruvate metabolism. Oncogene 39:1140–1151

    Article  Google Scholar 

  • Defeo-Jones D, Huang PS, Jones RE, Haskell KM, Vuocolo GA, Hanobik MG, Huber HE, Oliff A (1991) Cloning of cDNAs for cellular proteins that bind to the retinoblastoma gene product. Nature 352:251–254

    Article  CAS  Google Scholar 

  • Denisenko TV, Budkevich IN, Zhivotovsky B (2018) Cell death-based treatment of lung adenocarcinoma. Cell Death Dis 9:1–4

    Article  Google Scholar 

  • Dietel M, Bubendorf L, Dingemans AM, Dooms C, Elmberger G, García RC, Kerr KM, Lim E, López-Ríos F, Thunnissen E, Van Schil PE (2016) Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group. Thorax 71:177–184

    Article  Google Scholar 

  • Feng T, Wang Y, Lang Y, Zhang Y (2017) KDM5A promotes proliferation and EMT in ovarian cancer and closely correlates with PTX resistance. Mol Med Rep 16:3573–3580

    Article  CAS  Google Scholar 

  • Herbst RS, Morgensztern D, Boshoff C (2018) The biology and management of non-small cell lung cancer. Nature 553:446–454

    Article  CAS  Google Scholar 

  • Hou J, Wu J, Dombkowski A, Zhang K, Holowatyj A, Boerner JL, Yang ZQ (2012) Genomic amplification and a role in drug-resistance for the KDM5A histone demethylase in breast cancer. Am J Transl Res 4:247–256

    CAS  PubMed  PubMed Central  Google Scholar 

  • Jao K, Tomasini P, Kamel-Reid S, Korpanty GJ, Mascaux C, Sakashita S, Labbé C, Leighl NB, Liu G, Feld R, Bradbury PA (2018) The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer. Lung Cancer 123:22–29

    Article  Google Scholar 

  • Kinoshita T, Kudo-Saito C, Muramatsu R, Fujita T, Saito M, Nagumo H, Sakurai T, Noji S, Takahata E, Yaguchi T, Tsukamoto N (2017) Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma. Eur J Cancer 86:15–27

    Article  Google Scholar 

  • LaFave LM, Kartha VK, Ma S, Meli K, Del Priore I, Lareau C, Naranjo S, Westcott PM, Duarte FM, Sankar V, Chiang Z (2020) Epigenomic state transitions characterize tumor progression in mouse lung adenocarcinoma. Cancer Cell 38:212–228

    Article  CAS  Google Scholar 

  • McCann TS, Parrish JK, Hsieh J, Sechler M, Sobral LM, Self C, Jones KL, Goodspeed A, Costello JC, Jedlicka P (2020) KDM5A and PHF2 positively control expression of pro-metastatic genes repressed by EWS/Fli1, and promote growth and metastatic properties in Ewing sarcoma. Oncotarget 11:3818–3831

    Article  Google Scholar 

  • Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, Escriu C, Peters S (2017) Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(suppl 4):iv1-21

    Article  CAS  Google Scholar 

  • Qiu M, Xia W, Chen R, Wang S, Xu Y, Ma Z, Xu W, Zhang E, Wang J, Fang T, Hu J (2018) The circular RNA circPRKCI promotes tumor growth in lung adenocarcinoma. Cancer Res 78(11):2839–2851

    Article  CAS  Google Scholar 

  • Raisova M, Hossini AM, Eberle J, Riebeling C, Orfanos CE, Geilen CC, Wieder T, Sturm I, Daniel PT (2001) The Bax/Bcl-2 ratio determines the susceptibility of human melanoma cells to CD95/Fas-mediated apoptosis. J Invest Dermatol 117:333–340

    Article  CAS  Google Scholar 

  • Ren F, Shrestha C, Shi H, Sun F, Zhang M, Cao Y, Li G (2020) Targeting of KDM5A by miR-421 in human ovarian cancer suppresses the progression of ovarian cancer cells. Onco Targets Ther 13:9419–9428

    Article  CAS  Google Scholar 

  • Wang JZ, Xiang JJ, Wu LG, Bai YS, Chen ZW, Yin XQ, Wang Q, Guo WH, Peng Y, Guo H, Xu P (2017) A genetic variant in long non-coding RNA MALAT1 associated with survival outcome among patients with advanced lung adenocarcinoma: a survival cohort analysis. BMC Cancer 17:167

    Article  Google Scholar 

  • Ward RA, Fawell S, Floc’h N, Flemington V, McKerrecher D, Smith PD (2020) Challenges and opportunities in cancer drug resistance. Chem Rev 121:3297–3351

    Article  Google Scholar 

  • Yang GJ, Wang W, Mok SW, Wu C, Law BY, Miao XM, Wu KJ, Zhong HJ, Wong CY, Wong VK, Ma DL (2018) Selective inhibition of lysine-specific demethylase 5A (KDM5A) using a rhodium (III) complex for triple-negative breast cancer therapy. Angew Chem Int Ed 130:13091–13095

    Article  Google Scholar 

  • Yang GJ, Ko CN, Zhong HJ, Leung CH, Ma DL (2019) Structure-based discovery of a selective KDM5A inhibitor that exhibits anti-cancer activity via inducing cell cycle arrest and senescence in breast cancer cell lines. Cancers 11:92

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We acknowledge Jiaxing Second Hospital, Jiaxing China for providing the lab facilities.

Funding

This study was supported by Jiaxing City Scientific Research Project (Public Welfare Research Project) (No: 2018AY32001).

Author information

Authors and Affiliations

  1. Department of Respiratory Medicine, Jiaxing Second Hospital, Jiaxing, 314000, Zhejiang, China

    Hong Wu & Xun Hu

  2. Department of Thoracic Surgery, Jiaxing Second Hospital, Jiaxing, 314000, Zhejiang, China

    Lidong Xu

Authors
  1. Hong Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lidong Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xun Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

HW and XU designed the study. HU and LX performed the experimental work and collected the data for presented study. XH and LX carried out the statistical analysis. XH supervised the work and drafted the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Xun Hu.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Ethics approval

The study was approved by the research ethics committee of Jiaxing Second Hospital, Jiaxing Zhejiang, China (Approval No. 667JZ-2020).

Consent to participate

Informed written consent was obtained from all the patients before participation in the present study.

Consent for publication

Not applicable.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wu, H., Xu, L. & Hu, X. KDM5A regulates the growth and gefitinib drug resistance against human lung adenocarcinoma cells. 3 Biotech 12, 97 (2022). https://doi.org/10.1007/s13205-021-03018-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s13205-021-03018-w

Keywords

Search

Navigation